Mizuho analyst Graig Suvannavejh upgraded Corvus Pharmaceuticals (NASDAQ: CRVS) from Neutral to Outperform with a price target of $12.00 (from ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE